Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 1998

View Archived Issues

Therapy with losartan plus ACE inhibitors effective in heart failure patients

Clopidogrel likely to further reduce incidence of vascular events compared to aspirin in practice

PMA for KeraVision Ring accepted for filing

Xoma licenses LBP technology to Diagnostic Products

Another rotavirus vaccine gives promising results in phase II testing

Fujisawa announces marketing approval of Prograf in Mexico and launch in Taiwan

Astra to reevaluate development strategy for Allelix's recombinant PTH

Protegrin analogue safe in cancer patients receiving chemotherapy

Fortovase approved in Europe

Keratinocyte growth factor to enter phase II clinical trials

New neurokinin antagonists from Schering-Plough especially useful for asthma

Leo describes potent vitamin D3 derivatives with low calcemic activity

Dual 5-LO and COX-2 inhibitors for inflammatory disorders

Preparation and use of GH secretatogues disclosed by Merck & Co.

Therapeutics for cerebrovascular disorders in development at Nippon Chemiphar

Pharmacological profile of new acetylcholinesterase inhibitor: T-82

Antitumor imidazoacridone available for licensing from BTG

DAT inhibitor RTI-113 prevents cocaine consumption by rats

FDA advisory committee recommends clearance for Valstar

Nolvadex recommended for approval in U.S., to be copromoted by Zeneca and Roche

New biologic for breast cancer receives advisory committee approval

WHI reports design, synthesis and pharmacological evaluation of new agent for glioblastoma

Cytotoxic gigantecin analogue presented at ACS meeting

Receptor-selective retinoids under study at BMS

Pfizer/Neurogen anxiolytic advances in clinical trials

Fibrinogen antagonist NSL-96184 shows excellent antithrombotic potential

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...